PMGC Holdings Inc (ELAB) News

Pharma whales bottom feeding plankton

Load up folks, these prices
are a gift you shouldn't ignore.
Got myself another 1K @ 1.91
Too good to pass on......

Many more interesting reads will
follow soon. (We haven't even started)

an interesting read on twitter about ELAB
https://stocktwits.com/GatorMcKlusky/message/601468950

ELAB.....................https://stockcharts.com/h-sc/ui?s=ELAB&p=W&b=5&g=0&id=p86431144783

$3.05 +'50% Get out in $3s and wait for $2s is the game,
whoever holding float flipping for cheaper shares. Careful for now 
64 million shares traded on a 3m float 

$3.19 just a patience game now someone locked the float up. Let them play now. Buy dips before the Feb 7 UCLA conference.
Trading 20 times it's float already 
Buys under $3 a bonus next few weeks 

A $10 move yes once breaks through $4.02 and there discovery much more potential then ALUR balloon. Keep muscle mass
Maybe not $100 but there product will be of use to billions of obese people worldwide 

$100+ by Feb 7th! ELAB is the next DRUG!

Has a monster product for obesity and they will sell it to the largest bidder as a holding company. See $10+ in future 

ELAB........................................................weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee

$4.80 will it go after $11 today? 

Live the melting fat ass dream brothers🚀🚀🚀🚀🚀

$3.92 +'96% 

ELAB $3.50 + 75% break $4.02 zone could see $11s maybe it pulls an ALUR move. For now flipped out most here $3.40s 

ELAB $2.95 January 24 2025 - 8:00AM


PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB), today announced that Northstrive Biosciences Inc. (“Northstrive Biosciences”) has been invited to present at the upcoming symposium called Anti-Obesity Treatments: Challenges and Emerging Solutions organized by UCLA Metabolism Theme. UCLA Metabolism Theme is an initiative at UCLA David Geffen School of Medicine aiming to facilitate campus wide interdisciplinary research in the field of metabolism involving basic, clinical, and industry collaborationsThis timely symposium brings together industry leading, obesity focused clinicians, researchers, drug developers and investors to address the challenges brought up by weight loss treatments. Northstrive Biosciences has been invited to present lead asset EL-22, which leverages a first-in-class engineered probiotic approach for preserving muscle while on weight loss treatments.“The rise of anti-obesity medications has put the spotlight on the challenges being faced, particularly the management of muscle and bone loss associated with GLP-1 receptor agonists,” stated Orian Shirihai, MD, PhD, the Director of UCLA’s Metabolism Theme. “We organized this event to gather obesity’s leading opinion leaders to review the gaps and highlight the emerging solutions. I am pleased that Northstrive Biosciences has accepted our invitation to give a talk at the event.”Northstrive Biosciences will showcase EL-22, a first-in-class engineered probiotic designed to preserve muscle mass in patients undergoing weight-loss treatments, including GLP-1 receptor agonists. This groundbreaking therapeutic addresses a critical gap in current obesity treatments, where up to 50% of body weight lost is lean muscle mass—a side effect that has yet to be adequately addressed by approved therapies.[1][2] Studies show that approximately 30-50% of body weight lost with GLP-1 based therapy is lean muscle mass, a common side effect that has no currently approved treatment. Northstrive’s lead asset EL-22 is being developed as a potential combination therapy with GLP-1 receptor agonists for preserving muscle while on weight loss treatments.“We are looking forward to presenting EL-22 as a next-generation solution to the common muscle wasting side effect,” said Deniel Mero, Co-founder of Northstrive Biosciences. “We’re honored to contribute a lecture and are looking to connect with key opinion leaders, investors and established pharma companies in the obesity space.”Northstrive Biosciences’ management is scheduled to present on Friday, February 7th at 11:30 am PT.

$3.27 on obesity conference news

Party starting $3 +'50%

This juggling has to come
to an end.
Burn those shorts !

It won’t pop but explode to 100$ dudes!! Strap on your dildo dudes we going short hunting

60k traded no shorts available. where’s it got to go dudes!!!

20$ gap fill dudes!!!!
https://m.koreaherald.com/article/10400271

https://biz.chosun.com/en/en-science/2025/01/16/VPKAHH2JDNEEDKH3QTIJU3Y6GE/

Blue skies dudes!!!!
https://www.pmgenomics.ca/pmgenomics/

https://www.statnews.com/2025/01/15/readout-loud-podcast-eli-lilly-dave-ricks-obesity-trump-jpm/

Let’s go…… 🚀🚀🚀🚀🚀🚀

Take out the news 🚀🚀🚀🚀🚀

The perfect storm is brewing brother,
hold on to those shares !

Soak up the float, Explosion incoming🚀🚀🚀🚀

New Website
https://www.northstrivebio.com/pipeline

More hitting wires
PMGC Holdings Inc. Announces Name Change of Wholly Owned Subsidiaries
January 15 2025 - 9:30AM


Share On Facebook

PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) is pleased to announce the renaming of its wholly owned subsidiaries as part of a strategic effort to better align with the company's evolving business focus as a diversified holding company. Effective immediately, the following name changes have taken place:
Elevai Research Inc. is now PMGC Research Inc.
Elevai Biosciences, Inc. is now Northstrive Biosciences Inc.
About PMGC Research Inc. (formerly Elevai Research Inc.)

PMGC Research Inc. is a research and development subsidiary of PMGC Holdings Inc. focused on advancing the frontiers of scientific discovery. Currently, the company is leveraging Canadian research grants and partnering with leading Canadian universities to push the boundaries of innovation in the biosciences field. Through strategic collaborations, PMGC Research Inc. is dedicated to transforming scientific breakthroughs into real-world solutions that improve health and well-being.

About Northstrive Biosciences Inc. (formerly Elevai Biosciences, Inc.)

Northstrive Biosciences Inc. is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22 is leveraging a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

For more information, please visit www.northstrivebio.com.

Both PMGC Research Inc. and Northstrive Biosciences Inc. continue to focus on driving innovation and delivering transformative solutions in their respective fields.

For more information on PMGC Holdings Inc. and its subsidiaries, please visit www.pmgcholdings.com

About PMGC Holdings Inc.

PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.

Tidal wave Bigger than ever coming,,,,
https://www.biospace.com/business/dispatches-from-jpm-biogens-sage-buyout-offer-pfizers-obesity-play-more

Hail breakthrough brothers
https://ppubs.uspto.gov/dirsearch-public/patents/html/12194136?source=USPAT&requestToken=eyJzdWIiOiI2YzM5NDg5Yi0wYThiLTQ5ODQtOWMzNS1hMjJmNGIyOWVkMjYiLCJ2ZXIiOiIyZDZhYTNlMC1hYmMwLTRkNDEtYTZmNC03YjkzZjdhZDYyODUiLCJleHAiOjB9

I’m All Inn brother 🚀🚀🚀🚀🚀🚀

https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-going-all-in-obesity-drug-development-ceo-bourla-says-2025-01-13/

I’m ready brother
https://koreajoongangdaily.joins.com/news/2025-01-14/business/industry/At-JP-Morgan-Healthcare-Conference-Korean-pharmaceuticals-set-to-share-strategies-seal-deals-/2221706

Huge gap to 20$ dudes!!!

It’s the calm before the storm dudes!!
https://www.fiercebiotech.com/biotech/jpm25-day-1-fierce-biotech-daily-roundup

Healthcare dealmakers eye M&A resurgence in second Trump term

Private equity firms expected to spur deals
Investors await Trump's healthcare policies
Cancer treatments, weight-loss drugs among hot areas

https://www.reuters.com/markets/deals/healthcare-dealmakers-eye-ma-resurgence-second-trump-term-2025-01-13/

It's happening my friend,
being part of this 250 billion
Dollar market is HUGE ! ! !

Blue sky breakthrough on all screens dude!!!

It’s going to go viral next week , look at new video out https://www.jpmorgan.com/about-us/events-conferences/health-care-conference

Great video brother, we're definitely
in the right sector at the right time.

Get ready brother next week we making history https://www.cnbc.com/video/2025/01/10/ma-obesity-top-of-mind-for-investors-at-j-p-morgan-healthcare-conference-portal-innovations-ceo.html

EL-22 brother FDA green light

If on Monday, it can go up
with SpaceX's flight 7
Let's blast off, let the countdown
begin brother, it'll be a thing of
beauty.......

Monday morning can be the rocket news

They are completely out of ammo, time to cover$

They're running out of time IMHO

Are Shorts out of ammo brothers??

Hold on to your dirty underwears brother, Jet fuel 100% octane on deck

It’s a shake the cherries off the tree weak hands